US008486998B2
(12) United States Patent Elsohly et a1. (54)
(75) Inventors: Mahmoud A. Elsohly, Oxford, MS
(US); Waseem Gul, Oxford, MS (US); Mohammad Khalid Ashfaq, Oxford, MS (U S); Susan P. Manly, Oxford, MS
(Us) (73) Assignee: The University of Mississippi, University, MS (U S) Notice:
Subject to any disclaimer, the term of this patent is extended or adjusted under 35
U.S.C. 154(b) by 56 days.
(21) App1.No.:
12/936,204
(22) PCT Filed:
Apr. 3,2009
(86)
PCT N0.:
PCT/US2009/039472
§ 371 (0)0), (2), (4) Date:
Dec. 14, 2010
(87)
US 8,486,998 B2 Jul. 16, 2013
Epstein, W. L. 1994. Occupational poison ivy and oak dermatitis.
COMPOSITIONS FOR PREVENTION/PROPHYLACTIC TREATMENT OF POISON IVY DERMATITIS
(*)
(10) Patent N0.: (45) Date of Patent:
PCT Pub. No.: WO2009/146131
Dermatol Clin.12:511-516.
Gladman, A. C. 2006, Toxicodendron Dermatitus: Poison Ivy, Oak and Sumac. Wilderness and Enviromental Medicine, 17: 120-128. Symes, W. F. and Dawson, CR. 1954. Poison ivy urushiol. J. Am. Chem. Soc. 76:2959-2963.
Sunthankar, SV. and Dawson, CR. 1954. The structural identi?ca tion of the ole?nic components of Japanese Lac urushiol. J. Am. Chem. Soc. 76:5070-5074. MarkiewitZ, K. H. and Dawson, C. R. 1965. On the Isolation of
Allergenically Active Components of the Toxic Principle of Poison Ivy. J. Org. Chem. 30:1610-1613. Billets, S., Craig, J. C., Corbett, M. D. and Vickery, J. F. 1976. Component analysis of urushiol content of poison ivy and poison oak. Phytochemistry. 15: 533-535. Tyrnan, J. H. P. 1996. Studies in Organic Chemistry 52. p. 465-546. In Synthetic and Natural Phenols. Elsevier.
Xia, Z., Miyakoshi, T. andYoshida, T. 2004. Lipoxygenase-catalysed polymerization of phenolic lipids suggests a new mechanism for allergic contact dermatitis induced by urushiol and its analogs. Bio chemical and Biophysical Research Communication. 315:704-709. Byck, J. S. and Dawson, C. R. 1968. Assay of protein-quinone cou
pling involving compounds structurally related to the active principal ofpoison ivy. Anal. Biochem. 25:123-135. BeneZra, C. 1990. Molecular recognition in allergic contact dermatitis to natural products. Pure Appl. Chem. 62: 1251-1258. Kalish, R. S. 1991, Recent developments in the pathogenesiss of allergic contact dermatitis. Arch. Dermatol. 127:1558-1563.
PCT Pub. Date: Dec. 3, 2009
(Continued) (65)
Prior Publication Data
US 2011/0086900 A1
Apr. 14, 2011
Related US. Application Data
(60) Provisional application No. 61/042,118, ?led on Apr. 3, 2008. (51)
Int. Cl. A61K 31/215 C0 7D 205/00 (52) US. Cl. USPC
(58)
(2006.01) (2006.01)
........................................... .. 514/535; 560/20
Field of Classi?cation Search USPC
........................................... .. 560/20; 514/535
Primary Examiner * Shawquia Young (74) Attorney, Agent, or Firm * HershkovitZ & Associates, LLC
(57)
ABSTRACT
The present invention, in one or more embodiments, com
prises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptade cylcatechol (poison oak urushiol saturated congener) as com positions for the prevention and/ or prophylactic treatment of
contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for mak ing such compounds. Disclosed are compounds which are
See application ?le for complete search history.
effective for toleriZing and desensitiZing a subject against allergens contained in plants of the Anacardiaceae and Gink
References Cited
goaceae families comprising water soluble urushiol esters of
(56)
general formula (I) ToleriZing and desensitiZing mammals, PUBLICATIONS Eisohly, et al. Document No. 99:175452 (1983).*
Praiser, D. M., Ceilley, R. I., Le?1 31kg
w 458g m 81mg
m
av
x}?
58383 mfg if? ma! gm; 3mm a? T833 2 72 m as; wasiziimmw (Emu Emu Gran‘ 8mm Gray
9353
vahicie 3.8ug 458g 6.8%
Us
8 G 8.5 {9.5
iip
G {2.5 8,5 w
mp W52
0 U 85 {2.5 3
G 8.8 m5 28.5
V9
9 m 37.5 22.5
US. Patent
Jul. 16, 2013
Sheet 10 0f 21
Test #5‘, (Group 1) FIG. 4A
US 8,486,998 B2
US. Patent
Jul. 16, 2013
Sheet 11 0121
Test #3, (Group II)
FIG. 4B
US 8,486,998 B2
US. Patent
Jul. 16, 2013
Sheet 12 0121
Test?, (Group III) FIG. 4C
US 8,486,998 B2
US. Patent
Jul. 16, 2013
Sheet 13 0f 21
Test #3, (Graup / V)
FIG‘. 40
US 8,486,998 B2
US. Patent
Jul. 16, 2013
Sheet 14 0f 21
Test #3 (Group V)
FIG. 45
US 8,486,998 B2
US. Patent
Jul. 16, 2013
Sheet 15 0f 21
Fm’; ms: saws {W
a? 2
US 8,486,998 B2
rs as!
ums?iai miisnga
‘ WI
%
H182m5
% SQUQ Q 458g 8 568g
2; (J1(2:;
gage
S23v8
vahicie
CD‘Z I)
388g 458g 611mg
8mm}
2.5
US. Patent
Jul. 16, 2013
US 8,486,998 B2
Sheet 16 0f 21
Mai‘ ms: saw {i
ms?iai maiianga Vi? @ 3mg Q 4.5m; @ 51mg
%
H1s2w5am 151855515
mfg
Base
vahicie
453g 611mg
i
map
ma; my mm a? wasizii caiieiz?
Gmug W
m m? 8
r-baMgq
5.5
US. Patent
Jul. 16, 2013
Sheet 17 0121
US 8,486,998 B2
%
3. 811g
H182m5
Q 4. 511g E 5. 611g
2; (J1(2:;
$3858 8. N85181: 88mg 8? F2 m ms? 811185155 ?aii??? Gmu Emu Base W ‘a v 53
vahicie 388g 458g 611mg
9 0 Q 1.5
6 Q5 5.5 18.5
US. Patent
Jul. 16, 2013
Sheet 18 0f 21
US 8,486,998 B2
Group IV, Treated with ELl-21-57-3 and then challenged with urushiol
(Skin reaction at 72 hrs)
FIG. 6'